RegeneRx Biopharmaceuticals, Inc. (RGRX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
RegeneRx Biopharmaceuticals, Inc. (RGRX) trades at $0.0007. RegeneRx Biopharmaceuticals, Inc. focuses on developing Thymosin beta 4-based therapeutics for tissue and organ repair. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for RGRX: RGRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RGRX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RGRX: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →RegeneRx Biopharmaceuticals, Inc. (RGRX) Healthcare & Pipeline Overview
RegeneRx Biopharmaceuticals, Inc. is a biotechnology company specializing in the development of Thymosin beta 4-based therapeutics for tissue regeneration and repair. Their pipeline targets ophthalmic, cardiovascular, neurological, and dermatological conditions, positioning them within the regenerative medicine sector with strategic partnerships for global reach.
What Is the Investment Thesis for RGRX?
RegeneRx Biopharmaceuticals presents a high-risk, high-reward investment profile centered on its Thymosin beta 4 (Tβ4) technology platform. The company's value hinges on the successful clinical development and commercialization of its lead drug candidates, particularly RGN-259 for ophthalmic indications. Key catalysts include upcoming clinical trial results for RGN-259 in various eye conditions and potential regulatory approvals. The company's partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. offer avenues for international expansion and revenue generation. However, the company's small size, limited financial resources, and reliance on external funding pose significant risks. A negative P/E ratio of -0.02 and a substantial negative profit margin of -2249.8% highlight the company's current lack of profitability and dependence on future product success. The high beta of 4.73 indicates significant volatility relative to the market.
Based on FMP financials and quantitative analysis
RGRX Key Highlights
Market capitalization of $0.00B reflects the company's early stage and speculative nature.
- Gross margin of 100.0% indicates high potential profitability if products reach commercialization, though it currently reflects limited revenue.
- Negative P/E ratio of -0.02 underscores the company's current lack of earnings.
- Profit margin of -2249.8% highlights significant operating losses due to ongoing research and development expenses.
- Beta of 4.73 suggests the stock is significantly more volatile than the market average, reflecting the high-risk nature of biotechnology investments.
Who Are RGRX's Competitors?
RGRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RGRX's Key Strengths?
Proprietary Thymosin beta 4 (Tβ4) technology platform.
- Potential for regenerative medicine applications across multiple therapeutic areas.
- Strategic partnerships for global development and commercialization.
- Focus on unmet medical needs in ophthalmic, cardiovascular, and dermatological conditions.
What Are RGRX's Weaknesses?
Limited financial resources and reliance on external funding.
- Small size and limited infrastructure.
- Dependence on the success of its lead product candidates.
- High risk associated with clinical development and regulatory approval.
What Could Drive RGRX Stock Higher?
Clinical trial results for RGN-259 in dry eye syndrome.
- Clinical trial results for RGN-259 in neurotrophic keratitis.
- Advancement of RGN-352 into clinical trials for cardiovascular diseases.
- Development of RGN-137 for dermal wound healing.
- Expansion of strategic partnerships for global development and commercialization.
What Are the Key Risks for RGRX?
Clinical trial failures and regulatory setbacks.
- Competition from established pharmaceutical companies and other biotechnology firms.
- Patent expirations and generic competition.
- Limited financial resources and reliance on external funding.
- Dependence on the success of its lead product candidates.
What Are the Growth Opportunities for RGRX?
- RGN-259 for Dry Eye Syndrome: The global dry eye syndrome market is projected to reach $7.8 billion by 2028. RGN-259, as a preservative-free topical eye drop, has the potential to capture a significant share of this market by offering a regenerative approach to treating corneal damage and inflammation. Successful clinical trials and regulatory approval could drive substantial revenue growth for RegeneRx.
- RGN-259 for Neurotrophic Keratitis: Neurotrophic keratitis, a degenerative corneal disease, represents another significant market opportunity for RGN-259. The orphan drug designation pathway could accelerate regulatory approval and provide market exclusivity. The addressable patient population, while smaller than dry eye syndrome, offers potential for high pricing and revenue generation.
- RGN-352 for Cardiovascular Diseases: The market for cardiovascular disease treatments is substantial, with a global market size of hundreds of billions of dollars. RGN-352, with its potential to reduce inflammation and promote tissue repair in cardiovascular tissues, could address unmet needs in this market. However, clinical development and regulatory approval for cardiovascular indications are typically lengthy and expensive.
- RGN-137 for Dermal Wound Healing: The wound care market is driven by the increasing prevalence of chronic wounds, such as diabetic ulcers and pressure sores. RGN-137, as a topical gel for dermal wounds, could offer a regenerative approach to wound healing and scar reduction. The market is competitive, but a differentiated product with superior efficacy could gain market share.
- Strategic Partnerships and Licensing Agreements: RegeneRx's partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. provide opportunities for international expansion and revenue generation through licensing agreements and royalty payments. Expanding these partnerships to other regions and therapeutic areas could further drive growth and diversify revenue streams.
What Opportunities Does RGRX Have?
- Expanding partnerships to new regions and therapeutic areas.
- Securing orphan drug designations for specific indications.
- Advancing clinical trials and achieving regulatory approvals.
- Capitalizing on the growing market for regenerative medicine.
What Are RGRX's Competitive Advantages?
- Patented Thymosin beta 4 (Tβ4) technology platform.
- Strategic partnerships with established pharmaceutical companies for global reach.
- First-mover advantage in developing Tβ4-based therapeutics for specific indications.
What Does RGRX Do?
RegeneRx Biopharmaceuticals, Inc., founded in 1982 and based in Rockville, Maryland, is a biopharmaceutical company focused on developing therapeutic peptides, specifically Thymosin beta 4 (Tβ4), for tissue and organ protection, repair, and regeneration. Originally incorporated as Alpha 1 Biomedicals, Inc., the company changed its name in 2000 to reflect its evolving focus on regenerative medicine. RegeneRx's lead product candidate, RGN-259, is a preservative-free topical eye drop designed to regenerate corneal tissues damaged by injury, disease, or other pathologies, addressing conditions such as dry eye syndrome and neurotrophic keratitis. RGN-352 is an injectable formulation being developed to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications, aiming to reduce inflammation and promote tissue repair. RGN-137 is a topical gel intended for dermal wounds and the reduction of scar tissue formation. RegeneRx has established strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. to expand the global reach of its Tβ4-based therapeutics. The company's core technology centers on the regenerative properties of Tβ4, a naturally occurring peptide involved in wound healing and tissue repair processes.
What Products and Services Does RGRX Offer?
- Develops Thymosin beta 4 (Tβ4)-based therapeutics.
- Focuses on tissue and organ protection, repair, and regeneration.
- Creates topical eye drops for corneal regeneration (RGN-259).
- Develops injectable formulations for cardiovascular and neurological diseases (RGN-352).
- Formulates topical gels for dermal wounds and scar reduction (RGN-137).
- Partners with other companies for global distribution and development.
How Does RGRX Make Money?
- Develops and patents Tβ4-based therapeutic candidates.
- Out-licenses its technology and products to partners for development and commercialization in specific territories.
- Generates revenue through upfront payments, milestone payments, and royalties on product sales from its partners.
What Industry Does RGRX Operate In?
RegeneRx operates within the biotechnology industry, which is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The regenerative medicine market, where RegeneRx's Tβ4 technology is focused, is experiencing significant growth driven by an aging population and increasing demand for therapies that can repair and regenerate damaged tissues. Key competitors include companies developing novel therapies for ophthalmic, cardiovascular, and dermatological conditions. The industry is also subject to evolving regulatory landscapes and pricing pressures.
Who Are RGRX's Key Customers?
- Pharmaceutical companies (Lee's Pharmaceutical Group, GtreeBNT Co., Ltd.)
- Potential future customers: Patients suffering from dry eye syndrome, neurotrophic keratitis, cardiovascular diseases, neurological disorders, and dermal wounds.
- Healthcare providers who prescribe and administer RegeneRx's products.
Insider Activity
The most recent 12 insider filings for RegeneRx Biopharmaceuticals, Inc. break down as 0 sales and 12 purchases. On net that is roughly 7.1M shares acquired (about $313K) — insiders putting money in tends to read as conviction.
Key Financial Metrics
Return on equity for RegeneRx Biopharmaceuticals, Inc. stands at 60.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.55 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
RegeneRx Biopharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Company Profile
RegeneRx Biopharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Rockville, US. The company is led by CEO J. J. Finkelstein. RGRX has traded publicly since 2003.
RGRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying shows confidence in RegeneRx's future, suggesting belief in upcoming positive developments.
- Community sentiment has shifted positively, with discussions highlighting potential breakthroughs in their drug pipeline.
- The company's focus on innovative therapies aligns well with current healthcare trends, attracting investor interest.
- Recent partnerships and collaborations indicate growing recognition in the biotech space, enhancing credibility.
Bear Case
- Concerns about the timeline for clinical trials have surfaced, leading to skepticism among some investors.
- Market perception remains cautious due to the company's previous volatility, which could deter new investments.
- Negative sentiment from a few analysts has raised doubts about the sustainability of their recent advancements.
- RegeneRx's limited financial resources might hinder their ability to compete effectively in a crowded market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RGRX Latest News
No recent news available for RGRX.
RGRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RGRX.
Price Targets
Wall Street price target analysis for RGRX.
RGRX MoonshotScore
What does this score mean?
The MoonshotScore rates RGRX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: J. J. Finkelstein
CEO
J.J. Finkelstein has served as the CEO of RegeneRx Biopharmaceuticals, Inc. His background includes experience in managing and leading small biotechnology companies. His expertise lies in guiding companies through the complexities of drug development, clinical trials, and regulatory processes. He is responsible for overseeing the strategic direction of RegeneRx and fostering partnerships to advance the company's pipeline of Tβ4-based therapeutics.
Track Record: Under J.J. Finkelstein's leadership, RegeneRx has focused on advancing its lead product candidates, particularly RGN-259, through clinical trials. He has overseen the establishment of strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. to expand the global reach of RegeneRx's Tβ4 technology. His tenure has been marked by efforts to secure funding and navigate the challenges of developing novel therapeutics.
RGRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that RegeneRx Biopharmaceuticals, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited trading volume and liquidity compared to those listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significant risks due to the potential for lack of transparency and regulatory oversight. This tier is also known as the Pink Open Market.
- OTC Tier: OTC Other
- Limited liquidity and potential for price volatility.
- Lack of transparency and limited financial disclosures.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Potential for delisting or suspension of trading.
- Dependence on external funding and potential for dilution.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Strategic partnerships with established pharmaceutical companies (Lee's Pharmaceutical Group, GtreeBNT Co., Ltd.).
- Patented Thymosin beta 4 (Tβ4) technology platform.
- Focus on developing therapeutics for unmet medical needs.
- Ongoing clinical trials for lead product candidates.
What Investors Ask About RegeneRx Biopharmaceuticals, Inc. (RGRX) — Healthcare
What does RegeneRx Biopharmaceuticals, Inc. do?
RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing Thymosin beta 4 (Tβ4)-based therapeutics for tissue and organ protection, repair, and regeneration. Their lead product candidate, RGN-259, is a preservative-free topical eye drop designed to regenerate corneal tissues damaged by injury or disease.
What do analysts say about RGRX stock?
As of March 17, 2026, there is no readily available analyst coverage or consensus for RGRX stock due to its OTC listing and small market capitalization. The company's valuation is speculative and depends heavily on the successful clinical development and commercialization of its product candidates.
What are the main risks for RGRX?
The main risks for RegeneRx Biopharmaceuticals, Inc. include clinical trial failures, regulatory setbacks, competition from established pharmaceutical companies, and limited financial resources. The company's dependence on the success of its lead product candidates, particularly RGN-259, poses a significant risk. Patent expirations and generic competition could also impact future revenue.
What are the key factors to evaluate for RGRX?
Evaluate RGRX on fundamentals, analyst consensus, and risk factors. RegeneRx Biopharmaceuticals presents a high-risk, high-reward investment profile centered on its Thymosin beta 4 (Tβ4) technology platform. Not financial advice.
How frequently does RGRX data refresh on this page?
RGRX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RGRX's recent stock price performance?
RegeneRx Biopharmaceuticals, Inc. (RGRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Thymosin beta 4 (Tβ4) technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RGRX overvalued or undervalued right now?
RegeneRx Biopharmaceuticals, Inc. (RGRX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RGRX before investing?
Before investing in RegeneRx Biopharmaceuticals, Inc. (RGRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or inconsistent.
- AI analysis pending for RGRX.